Newsroom

January 17, 2013 – Velomedix gets Health Canada approval for VELOCITY trial. International Report. Medical Device Daily. Vol 17, No 12.
Velomedix (Menlo Park, California), a medical device company specializing in the field of therapeutic hypothermia, has received Health Canada approval for its VELOCITY pilot study in addition to previously reported U.S. IDE approval (Medical Device Daily, Nov. 30, 2012).

November 30, 2012 – Product Briefs, Medical Device Daily, Vol 16, No 32.
Velomedix (Menlo Park, California) has received investigational device exemption (IDE) approval from the FDA to expand the design of its VELOCITY pilot clinical trial.

February 15, 2012 – NewCo on the Block Velomedix gets IDE to evaluate rapid cooling system for AMI. Amanda Pedersen. Medical Device Daily, Vol 16 No 31.
Inducing hypothermia to treat acute events such as cardiac arrest, heart attack, and acute ischemic stroke is nothing new. But one company has developed a system that, if approved, could surpass all existing hypothermia systems in terms of cooling speed.

February 9, 2012 – Financings Roundup, Medical Device Daily, Vol 16, No 27.
Velomedix (Menlo Park, California) reported closing a $10.2 million Series B financing and has appointed Jeff Gold as its CEO and Michael Moore as its VP of operations.

April 1, 2011 – Is Therapeutic Hypothermia Finally Heating Up? Mary Stuart, Start-Up, article #2011900073.
For over a decade, medical device companies have spent hundreds of millions of dollars trying to master the therapeutic benefits of lower body temperatures. Patience and perseverance might be paying off.